# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $9 pri...
GUIDANCERockwell Medical updates its 2024 guidance as follows: Updated 2024 Guidance (As of August 8, 2024)Updated 2024 Guidanc...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $9 pri...
Rockwell Medical (NASDAQ:RMTI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0....